Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page
- Check5 days agoChange DetectedA recruitment status line indicating no participant enrollment was added. Additionally, new help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), the Interventional label formatting was refined from 'Intervention / Treatment' to 'Intervention/Treatment', and a site revision stamp 'Revision: v3.6.0' was introduced.SummaryDifference0.6%

- Check12 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5. This reflects a metadata version bump for the study page rather than any substantive alteration to the study details.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4, representing a platform update. This change reflects an underlying improvement to the site's build rather than the displayed study content.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page now shows Revision: v3.5.3, replacing v3.5.2. This reflects a site-wide version update and does not change the study details or user interactions.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision note updated from v3.5.0 to v3.5.2 on the page.SummaryDifference0.1%

- Check91 days agoChange DetectedAdded a site revision note: v3.5.0 and removed the previous revision note: v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.